|
|
350 Hills St, Suite 106
Richland, WA 99354 USA
phone:1-509.375.1202
fax:
|
|
| Symbol |
ISR |
| Exchange |
AMEX |
| Founded |
1998 |
| Employees |
37 |
|
|
| isoray.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Cancer treatments using Cesium 131 radioisotope...
Currently treating-
Brain cancers- Glio, Mets and Mengi
Head and Neck cancer
Lung cancer- Primary and Mets
Colon Cancer
Prostate Cancer
Ocular cancer |
|
| Management |
| Dwight Babcock, Chairman and Chief Executive Officer; Fred Swindler, Vice President, Quality Assurance/Regulatory Affairs; William A. Cavanagh
Vice President, Research and Development; Lane Bray,
Chief Chemist; |
| |
|
|
|
|
|
|
|
| Keywords |
| Brain cancer, Lung cancer, Head and neck cancer, Ocular cancer, Colon cancer, Prostate cancer, Breast cancer, radiation treatment,oncology, urology, cancer, brachytherapy, radiation oncology, thoracic surgeons, neurosurgeons |
|
|
|
| Description |
|
IsoRay Medical™ provides innovative solutions for the treatment and diagnosis of disease using medical isotopes. Cesium-131, a seed brachytherapy radioisotope, is the Company’s powerful new treatment for prostate cancer; brachytherapy is a one-time, minimally invasive procedure that involves the placement of tiny seeds containing a radioactive isotope inside the prostate to kill malignant cells. Compared to other prostate brachytherapy isotopes on the market, Cesium-131 has a higher average energy, which enhances uniformity in radiation, and also has the shortest half-life, which limits side effects and increases the drug’s biological effective dose. This later-stage biotechnology company’s brachytherapy isotope received FDA approval in 2003, and the Company expects to broaden its treatment options with the development of protocols for the treatments of breast, liver, lung, pancreatic, and other cancers and malignancies. |
|
| Products / Services |
Cesium-131 brachytherapy seed.
Cesium-131 liquid form
Iotrex I-125 liquid form
|
|
| Technology / Differentiation |
| Cesium-131 has the highest energy and shortest half life (9.7 days) for use in low dose internal radiation |
|
| Market / Customers |
Major Medical Centers
Regional and local hospital groups
Local outpatient centers
|
|
| Competitors / Substitutes / Alternatives |
Bard and Oncura using Palladium-103 and Iodine-125, all of which have significantly longer half-lives and lower energy outputs than that of Cesium-131
|
|
| Strategy |
Treat cancers throughout the body using Cs-131. Unique is our universal FDA clearance for the treatment of any tumor in any body site.
|
|
| Funding |
| Publicly traded company on AMEX. Symbol (ISR) |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members